175 related articles for article (PubMed ID: 23758044)
1. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.
Mizoguchi I; Yoshimoto T; Katagiri S; Mizuguchi J; Tauchi T; Kimura Y; Inokuchi K; Ohyashiki JH; Ohyashiki K
Cancer Sci; 2013 Sep; 104(9):1146-53. PubMed ID: 23758044
[TBL] [Abstract][Full Text] [Related]
2. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.
Ohyashiki JH; Ohtsuki K; Mizoguchi I; Yoshimoto T; Katagiri S; Umezu T; Ohyashiki K
Drug Des Devel Ther; 2014; 8():1151-9. PubMed ID: 25187697
[TBL] [Abstract][Full Text] [Related]
3. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV
Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961
[TBL] [Abstract][Full Text] [Related]
4. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
[TBL] [Abstract][Full Text] [Related]
5. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
6. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
[TBL] [Abstract][Full Text] [Related]
7. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
8. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
10. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
11. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
12. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
[TBL] [Abstract][Full Text] [Related]
13. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Shin S; Kim JA; Kim HS; Cho EH; Kwak JY
Leuk Res; 2012 Jun; 36(6):689-93. PubMed ID: 22398220
[TBL] [Abstract][Full Text] [Related]
15. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
[TBL] [Abstract][Full Text] [Related]
17. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
18. [Sustained deep molecular response over eight years after discontinuation of imatinib for chronic myeloid leukemia].
Takano H; Nagata K; Wanabe D; Ohki M; Kato A
Rinsho Ketsueki; 2014 Dec; 55(12):2414-7. PubMed ID: 25744042
[TBL] [Abstract][Full Text] [Related]
19. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
20. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
